The objective of this study was to identify disease-causing mutations in a Sri Lankan male child presenting with ambiguous genitalia and psychomotor delay using the exome sequencing approach. A novel mutation in the aristaless-related homeobox (ARX) gene causing a hemizygous nucleotide substitution in exon 5 was identified (NM_139058.2 (ARX): c.1614G>T; p.K538N). This change causes a nonsynonymous substitution in the aristaless domain within the ARX protein which is predicted to be deleterious. This is the first reported case of ambiguous genitalia and psychomotor delay associated with this novel missense mutation within the ARX protein, and it highlights the value of exome sequencing even in sporadic cases.

Bashamboo A, McElreavey K: Gene mutations associated with anomalies of human gonad formation. Sex Dev 7:126-146 (2013).
Bonneau D, Toutain A, Laquerriere A, Marret S, Saugier-Veber P, et al: X-linked lissencephaly with absent corpus callosum and ambiguous genitalia (XLAG): clinical, magnetic resonance imaging and neuropathological findings. Ann Neurol 51:340-349 (2002).
Ekşioğlu YZ, Pong AW, Takeoka M: A novel mutation in the aristaless domain of the ARX gene leads to Ohtahara syndrome, global developmental delay and ambiguous genitalia in males and neuropsychiatric disorders in females. Epilepsia 52:984-992 (2011).
Gécz J, Cloosterman D, Partington M: ARX: a gene for all seasons. Curr Opin Genet Dev 16:308-316 (2006).
Hartmann H, Uyanik G, Gross C, Hehr U, Lücke T, et al: Agenesis of the corpus callosum, abnormal genitalia and intractable epilepsy due to a novel familial mutation in the aristaless-related homeobox gene. Neuropediatrics 35:157-160 (2004).
Kato M, Das S, Petras K, Kitamura K, Morohashi K, et al: Mutations of ARX are associated with striking pleiotropy and consistent genotype-phenotype correlation. Hum Mutat 23:147-159 (2004).
Ogata T, Matsuo N, Hiraoka N, Hata J: X-linked lissencephaly with ambiguous genitalia: delineation of further case. Am J Med Genet 94:174-176 (2000).
Sherr EH: The ARX story (epilepsy, mental retardation, autism, and cerebral malformations): one gene leads to many phenotypes. Curr Opin Pediatr 15:567-571 (2003).
Shoubridge C, Fullston T, Gécz J: ARX spectrum disorders: making inroads into the molecular pathology. Hum Mutat 31:889-900 (2010).
Spinosa MJ, Liberalesso PBN, Vieira SC, Olmos ASF, Löhr A Jr: Lissencephaly, abnormal genitalia and refractory epilepsy - case report of XLAG syndrome. Arq Neuropsiquiatr 64:1023-1026 (2006).
Uyanik G, Aigner L, Martin P, Grob C, Neumann D, et al: ARX mutations in X-linked lissencephaly with abnormal genitalia. Neurology 61:232-235 (2003).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.